Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
The first African American actor to play the lead role in Les Misérables on Broadway has died, aged 21.
Crisis talks are to be held on the future of curry houses as cheap supermarket deals and immigration rules threaten the £4 billion industry.
Rain expected in the next 24 hours - no surprise there with it being a Bank Holiday - but there'll also be some brighter skies in places.